@YaleCancer profile picture
Yale Cancer Center @YaleCancer

Yale Cancer Center is a collaboration between renowned cancer researchers and physicians @Yale and @SmilowCancer.

Joined September 2012
  • Tweets 10,029
  • Following 1,803
  • Followers 17,239
4,227 Photos and videos
Tomorrow starting at 11am CEST/5am EST at @EHA_Hematology EHA Congress, @Dr_AmerZeidan and Dr. Nikolai Podolsev will present study results during the 'Novel Treatments in #AML' session at #EHA26. pag.virtual-meeting.org/EHA/… @SmilowCancer @YaleHematology
3
10
414
.@SanjayAnejaMD brought #AI in #cancer care to life at the @WestportLibrary during a compelling talk on the hope, hype & reality of this fast-moving field. From #radiology and #pathology to drug discovery, the EHR, medical scribes, and even insurance and billing, he explored where AI is already making an impact—and where big questions still remain. @SmilowCancer @YaleRadOnc @YaleMed @YNHH #WestportCT
2
6
433
Study results from Drs. Kwasi Ofori and @kturaga found #PeritonealMetastases often evade detection by ctDNA assays, despite occurring in up to 9.4% of pts with stage III #ColonCancer. Peritoneal recurrence was more common in ctDNA- than ctDNA patients, suggesting limited tumor DNA shedding into the bloodstream. medicine.yale.edu/cancer/pub… @SmilowCancer @AnnSurgOncol

Peritoneal Metastases Evade Circulating Tumor DNA Detection

This study investigates the limitations of circulating tumor DNA (ctDNA) surveillance in stage II–III colon cancer, showing reduced detection of isolated

medicine.yale.edu
1
2
6
728
A study from @RongFan8 and @sidichen highlights spatial CRISPR screening's potential to transform #cancerresearch by enabling spatial analysis of genetic and RNA interactions in complex tissues, providing insights into tumor biology, immune evasion, and RNA regulatory networks. medicine.yale.edu/cancer/pub… @SmilowCancer @NatureBiotech

Spatial CRISPR Unveils RNA Roles in Tumor Growth and Immunity

This study introduces Perturb-DBiT, a method enabling spatially resolved CRISPR screens and transcriptomics in tissues, uncovering genetic and RNA-level

medicine.yale.edu
4
14
5,209
Yale Cancer Center retweeted
Cancer Discovery@CD_AACR
Jun 10
Look back at #AACR26— David A. Braun, MD, PhD, accepts the 2026 Cancer Discovery Early Career Award at the AACR Journals Reception. Learn more: brnw.ch/21x3fb7 @BraunMDPhD @YaleCancer @YaleMed
7
15
1,404
Yale Cancer Center retweeted
Smilow Cancer Hospital
@SmilowCancer
Jun 6
Join @SanjayAnejaMD Thursday, June 11, 7pm at @WestportLibrary for a free discussion on “AI in Cancer Treatment. Learn how #AI is helping improve #cancer diagnosis, symptom monitoring, and #clinicaltrial matching. ➡️Register: westportlibrary.org/event/ai… @YaleCancer
1
1
4
401
Scientists have identified proteins that could signal increased #lungcancer risk & a drug that could reduce the odds of a tumor developing. “This is the big ‘if,’” said @DrRoyHerbst. "Will it be clinically significant? Will we be able to block this sufficiently at the right stage to prevent cancer?” nytimes.com/2026/06/04/well/… @SmilowCancer @AgrawalNina @nytimeswell

Early Research Suggests a Path to Predict and Prevent Lung Cancer

Scientists have identified proteins that could signal increased lung cancer risk, as well as a drug that could reduce the odds of a tumor developing.

nytimes.com
1
5
476
Congratulations to Nikolai Podoltsev, MD, PhD, @YaleHematology who was presented with The Fred S. Kantor Teacher of the Year Award by the residents of the @YaleMed @TradIMYale program. @SmilowCancer @MarkDSiegel1 @Dr_AmerZeidan
1
3
33
5,910
Congratulations to Aniketh Tadepalli of the @GeorgeGoshuaMD Lab, as he was selected as a recipient of an @ASH_hematology HONORS (Hematology Opportunities for the Next Generation of Research Scientists) Award. @YaleHematology @YaleHemOnc @YaleMed #ASHAwards #Fight4Hematology
1
3
13
881
Yale Cancer Center retweeted
Annie Heffernan@a_e_heffernan
Jun 5
Please join us for our next webinar! Dr. Elizabeth Claus will present preliminary findings from @gliomaregistry's germline testing study for cancer genes in people with glioma & discuss what these findings may mean for patients & their family members. 🔗yale.zoom.us/j/98159035553
2
3
438
.@JensaMorrisMD joined @thecurbsiders podcast for "Oncology for the Hospitalist" and discussed topics like symptom management, prognosis, and hospice care. thecurbsiders.com/curbsiders… @SmilowCancer @SmilowHospSvc
2
1
6
576
The new President of @ASCO, Dr. Beth Mittendorf @ASCOPres, joins #YaleCancerAnswers tonight at 7:30pm to discuss exciting developments from the recent #ASCO26 Annual Meeting. 🎧 Listen live @wnpr 🔁 Download via @ApplePodcasts 💻 Listen later @YouTube @SmilowCancer @DanaFarber
1
8
24
1,967
On #BetweentheLines with @CancerNetwrk, Dr. Sarah Goldberg @YaleThoracic discusses #amivantamab every 4 weeks plus lazertinib as a first-line treatment for EGFR-mutated advanced #NSCLC. cancernetwork.com/view/clini… @SmilowCancer

Clinical Context & MARIPOSA Efficacy in 1L EGFRm NSCLC | CancerNetwork

New data show amivantamab plus lazertinib boosts survival and brain control in EGFR lung cancer, with convenient Q4W injection tips.

cancernetwork.com
2
784
A study from Drs. @mleapman Xiaomei Ma @YaleSPH highlights how PSMA-PET imaging may shift #prostatecancer treatment patterns by detecting previously hidden metastases. medicine.yale.edu/cancer/pub… @SmilowCancer @YaleCOPPER

PSMA-PET Linked to Advanced Prostate Cancer Treatments

This study investigates how PSMA-PET imaging for prostate cancer leads to earlier use of advanced therapies compared to traditional bone scans, impacting

medicine.yale.edu
1
5
519
Study results from @Dr_AmerZeidan colleagues in @NEJM demonstrate an all-oral regimen of decitabine–cedazuridine plus venetoclax is a viable treatment option for patients with #AML. 47% of pts achieved complete response & 63% had a complete or partial response. medicine.yale.edu/cancer/pub… @SmilowCancer @YaleHematology @OncoAlert

All-Oral Therapy Improves Outcomes in AML Patients

This study investigates the safety and efficacy of an all-oral decitabine-cedazuridine plus venetoclax regimen for newly diagnosed acute myeloid leukemia,

medicine.yale.edu
1
7
16
1,606
Findings from a study by Dr. Barbara Burtness highlight #amivantamab as a promising treatment option for patients with recurrent or metastatic #HNSCC who have exhausted standard therapies. medicine.yale.edu/cancer/pub… @SmilowCancer @JCO_ASCO #ASCO26

Amivantamab Boosts Response in Advanced Head and Neck Cancer

This study investigates amivantamab in recurrent/metastatic head and neck cancer, showing a 42% response rate and durable antitumor activity after prior

medicine.yale.edu
1
7
403
.@MaxStahlMD will present "Expanding the Arsenal Against #Leukemia and #MyelodysplasticSyndromes' this afternoon at 12:21pm CDT. The oral abstract session will be co-chaired by @Dr_AmerZeidan. meetings.asco.org/meetings/2… @SmilowCancer @YaleHematology @ASCO
3
10
575
.@vedangiri will present 'Clinical Implications of Germline Variants in #ProstateCancer' and also serve as a panelist in an oral abstract session this morning at 11:21am CDT. #ASCO26 meetings.asco.org/meetings/2… @SmilowCancer @ASCO
1
6
337
Stem cell transplantation is the most cost-effective option for long-term care of #sicklecelldisease in adults compared to gene therapy and standard of care treatment, according to new research from @GeorgeGoshuaMD published in @BloodPortfolio. ➡️ashpublications.org/blood/ar… @SmilowCancer @ASH_hematology
6
22
5,772
Load more